CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic myeloid leukemia.
  
  

  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with chronic myeloid leukemia.
  
  LEARNING OBJECTIVES

  • Evaluate factors, including age, comorbidities, personal preferences and side-effect profile, that contribute to the selection and sequencing of therapies for chronic-phase CML, and counsel patients regarding personalized treatment recommendations.
  • Assess the means by which tyrosine kinase inhibitors (TKIs) inhibit CML growth and progression, and recollect which of these agents are available to patients with each phase of the disease.
  • Interrogate available data on the feasibility of TKI discontinuation for patients with a sustained response to therapy, and identify appropriate candidates for this approach.
  • Review the mechanism of action of and published efficacy and safety data with STAMP (specifically targeting the ABL myristoyl pocket) inhibitors for CML, and appreciate the current role of these agents in the management of newly diagnosed and relapsed/refractory disease.
  • Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapeutic agents commonly employed for patients with CML to support quality of life and continuation of treatment.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: This educational activity for 2.25 contact hours is provided by RTP during the period of May 2025 to May 2026.
  
  This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.
  
  Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2025 to May 2026.
  
  This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.
  
  ONCC/ILNA CERTIFICATION INFORMATION
  The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2025/CML/ILNA.
  
  ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  FOR SUCCESSFUL COMPLETION
  Audio Program: This NCPD activity consists of an audio component. To receive credit, the participant should review the NCPD information, listen to the MP3s, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/CML/NCPD. The corresponding video program is available as an alternative at ResearchToPractice.com/ONS2025/CML/Video.
  
  Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2025/CML/Video/NCPD. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONS2025/CML.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ilene Galinsky, RN, BSN, MSN, ANP-C
  Senior Adult Research Program Nurse Practitioner
  Adult Leukemia Division
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committees: Autolus Therapeutics, Blueprint Medicines, Bristol Myers Squibb, GSK, Novartis; Consulting Agreements: Novartis.
  
  Michael J Mauro, MD
  Director, Chronic Myeloid Leukemia Program
  Attending Physician, Leukemia Service
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committees and Consulting Agreements: Bristol Myers Squibb, Enliven Therapeutics, Novartis, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Enliven Therapeutics, Novartis, Sun Pharma Advanced Research Company (SPARC), Sun Pharmaceutical Industries Ltd, Terns Pharmaceuticals.
  
  Neil P Shah, MD, PhD
  Edward S Ageno Distinguished Professor in Hematology/Oncology
  Director, UCSF Molecular Medicine Residency Program
  Chair, National Comprehensive Cancer Network CML Guidelines Panel
  University of California, San Francisco
  San Francisco, California
  
  Contracted Research: Kumquat Biosciences; Honoraria: Novartis (Delphi panel).
  
  Sara M Tinsley-Vance, PhD, APRN, AOCN
  Nurse Practitioner and Researcher
  Moffitt Cancer Center
  Tampa, Florida
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
  
  RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  These activities are supported by an educational grant from Novartis.
  
  Release date: May 2025
  Expiration date: May 2026
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.